| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.2 | 0.3 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.15 | 0.3 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.3 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |